Abbvie Inc
NYSE:ABBV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
138.08
203.87
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Abbvie Inc
NYSE:ABBV
|
313.5B USD | 9.8 | ||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
158.1B USD | 10.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118B USD | 12.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
112B USD | 4.9 | ||
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 457.2 | |
AU |
CSL Ltd
ASX:CSL
|
135.8B AUD | 12.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 6.2 | ||
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 23 | |
NL |
argenx SE
XBRU:ARGX
|
35B EUR | 19.3 | ||
US |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
32.7B USD | 17.3 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.